Red cell receptors provide unique entry points for Plasmodium parasites to initiate blood-stage malaria infection. Parasites encode distinct ligands that bind specifically to both highly abundant and low-copy receptors. Recent advances in the understanding of molecular and structural mechanisms of these interactions provide fundamental insights into receptor-ligand biology and molecular targets for intervention.
INTRODUCTION
A total 40% of the world's population is at risk for malaria leading to 8 00 000 deaths each year, predominantly in children. Malaria is caused by Plasmodium parasites which have a complicated lifecycle involving two different hosts, the Anopheles mosquito and the human, and three distinct stages of development: exo-erythrocytic, erythrocytic, and sporogonic stage. All stages are required to establish an infection and continue the cycle of transmission.
Within the human host, the erythrocytic stage consists of multiple cycles of red blood cell (RBC) invasion, replication, and lysis that lead to the anemia and fatigue associated with this disease. RBC invasion occurs in four distinct steps: lowaffinity interactions between the merozoite and RBC; apical reorientation and tight junction formation; active invasion and surface shedding; and formation of the parasitophorous vacuole for parasite replication. The first two steps rely on distinct receptor-ligand interactions between the host RBC and Plasmodium merozoite that are essential for parasite survival. Recently, great strides in understanding these interactions have been made and those efforts are described here. & ].
GLYCOPHORIN A AND B
Glycophorin A (GpA) is the most abundant glycoprotein on the surface of the RBC with 1 million copies per cell (Table 1) [2] . GpA is a single span transmembrane protein and part of a gene family that includes Glycophorin B (GpB) and Glycophorin E (GpE). GpB and GpE arose from gene duplication and share 95% sequence similarity and exon structure with GpA [4] . GpA is comprised of seven exons and exons 2 through 6 form the mature receptor. In contrast, the mature form of GpB consists of exons 2, 4, and 5. Exon 5 forms a constitutive transmembrane dimer that allows for both homodimers and heterodimers of GpA and GpB on the RBC surface [4] .
Mature GpA is heavily glycosylated with 16 Olinked glycans and 1 N-linked glycan on exons 2 and 3 that make up 50% of the molecular weight of the receptor [2, 4, 52] . Five O-linked glycans are located in exon 3 and are unique to GpA [2, 4, 52] . O-linked glycosylation on GpA is essential for binding to P. falciparum EBA-175, a member of the erythrocyte binding like (EBL) family of proteins ( Fig. 1b , Table  2 ) [17] . Region II of PfEBA-175 (RII-175) contains two Duffy binding like (DBL) domains that bind to GpA [18] . The crystal structure of RII-175 in complex with a-2,3-sialyllactose, a trisaccharide similar to Olinked glycans from GpA, revealed that the glycan binding sites are located at the dimer interface of RII-175 [16] implicating multimeric assembly of PfEBA-175 around a dimeric GpA during invasion [19 & ,21 & ]. Recently, production of fully glycosylated recombinant GpA (rGpA) in a mammalian tissue culture system enabled careful interrogation of the binding requirements for malaria infection [20 && ,22] . This system overcomes the poor yield, poor solubility, and contamination with GpB observed when GpA is extracted from RBCs. Multiple glycans in exon 3 of GpA are critical for P. falciparum invasion as mutation of three glycosylation sites within, or elimination of, exon 3 from rGpA abrogated binding to RII-175 [20 && ]. These glycans are also critical during in-vitro infection as loss of these glycosylation sites prevented inhibition of P. falciparum growth observed with rGpA [20 && ]. Therefore, PfEBA-175 differentiates between GpA and GpB by engaging glycans unique to GpA [20 && ]. It is possible that GpB arose because of evolutionary pressure driven by malaria infection to lose the PfEBA-175 binding site in GpA [20 && ]. Finally, GpB is engaged by PfEBL-1, a related protein to PfEBA-175 [24, 25] , although little is currently known about the mechanisms of this interaction ( Table 2) . PfMSP1 83, a member of the PfMSP1 complex, also binds to GpA purified from RBCs (Fig. 1a , Table  2 ) [23 & ]. Binding is not affected by trypsin or neuraminidase treatment and contrasts that of PfEBA-175 binding to GpA [18] . Trypsin treatment cuts GpA at two arginine residues in exon 3 and removes all but three glycans whereas neuraminidase
KEY POINTS
Malaria parasites must engage distinct red cell receptors for disease pathogenesis.
Multimeric assembly is critical for receptor-ligand engagement.
Parasites engage a wide range of red cell receptors to ensure invasion.
Identification of novel receptors and ligands informs receptor biology and host-pathogen interactions. ]. GpA can form a complex with Band 3 [2] and the PfMSP1 83 : GpA interaction likely augments the Band 3 contacts mediated by other PfMSP1 complex components ( Fig. 1a ). It is not yet clear how these two Plasmodium proteins can bind the same receptor region during invasion. However, it is plausible that PfMSP-1 binding occurs first during the initial cellcell contact and is supplanted by PfEBA-175 during tight junction formation and invasion.
GLYCOPHORIN C AND D
Glycophorin C (GpC) and Glycophorin D (GpD) are 40 kDa single span transmembrane glycoproteins unrelated to GpA/B/E and are present on the surface of RBCs in levels of 143 000 and 82 000 copies/cell, respectively (Table 1) [2, 5] . GpD results from an alternate start codon in exon 2 generating a protein that is 22 amino acids shorter; however, both proteins retain the cytoplasmic domain that is responsible for binding to the cytoskeleton [2] . GpC is heavily glycosylated with 1 N-linked glycan and 12 O-linked glycans. The alternate start codon of GpD eliminates the N-linked glycan and 6 O-linked glycans [2] .
GpC, but not GpD, is the receptor for PfEBA-140, another member of the EBL family ( Fig. 1c , Table 2 ) [27] . PfEBA-140 is unable to bind RBCs lacking GpC or lacking exon 2 of GpC, and antibodies targeting exon 2 of GpC block binding of PfEBA-140 to normal RBCs [27] . Together, these data argue that exon 2 is critical for binding. However, PfEBA-140 cannot bind GpC lacking the single N-linked glycan, indicating that this glycan in exon 1 also contributes to the GpC:PfEBA-140 interaction [28] .
Crystal share an overall fold with PfEBA-175, although RII-140 is monomeric instead of dimeric [26 && ,29] . F1 and F2 use the same region of the DBL domain to bind receptor glycans and these receptor binding pockets are structurally similar to each other, but distinct from the pockets in PfEBA-175 [26 && ]. However, mutational data revealed that the binding pocket in F1, but not F2, is essential for receptor binding [26 && ]. Polymorphisms in the F1 domain of PfEBA-140 alter receptor specificity and affinity [30, 53] . The polymorphism I185 V is located in the F1 binding pocket [26 && ], and parasite strains with V185 have reduced binding to RBCs compared to strains with I185 [30, 53] . The larger Ile creates a tight binding pocket for glycans in F1, and substitution by the smaller Val creates a cavity in the glycan binding pocket increasing solvent accessibility and reducing affinity for the receptor [26 && ]. The structure of EBA-140 has answered a number of questions relevant for engagement of GpC although the exact mechanism remains to be determined.
DUFFY ANTIGEN/RECEPTOR FOR CHEMOKINES
The Duffy antigen/receptor for chemokines (DARC) is a 35-50 kDa glycoprotein with seven transmembrane spanning regions and three N-linked glycans ( Table 1 ) [1] . It is expressed on the surface of RBCs and endothelial tissue and belongs to the G proteincoupled receptor family [1, 3] . DARC exists with either a glycine or an aspartate at amino acid position 42 resulting in the Duffy blood groups Fy a and Fy b , respectively. A Fy-null phenotype is also observed and is caused by a mutation of the GATA consensus translation sequence that eliminates DARC expression in RBCs but not in endothelial tissues. In DARC expressing erythrocytes, DARC is present at levels of 6000-13 000 copies/cell. Antibody staining using the DARC-specific antibody Fy 6 that recognizes amino acids 19-26 of DARC shows that levels of DARC are 50% greater in reticulocytes than erythrocytes [1] .
DARC is the receptor for Duffy binding protein (DBP) ligand from Plasmodium vivax (PvDBP) and Plasmodium knowlesi (Pk), and PvDBP is the sole member of the EBL family found in P. vivax (Fig. 1D , Table 2 ) [32] . Loss of DARC on RBCs is protective against P. vivax malaria making DBP a high-priority vaccine candidate [54] . DBP contains a single DBL domain in Region II (RII-DBP) that is sufficient to bind DARC on RBCs.
Residues 1-60 form the N-terminal ectodomain of DARC (DARC 1-60 ) and are sufficient for DBP binding [32, 33] . In the absence of DARC 1-60 , PvDBP is monomeric in solution [34] consistent with the monomeric structure of PkDBPa, which represents the unbound monomeric form of DBP [35] . Strikingly, addition of DARC 1-60 induces dimerization of PvDBP to form an oligomeric complex [34] . Two distinct crystal structures of the PvDBP : DARC complex have been determined: a heterotrimer (2 RII-DBP : 1 DARC) and a heterotetramer (2 RII-DBP : 2 DARC) [31 && ]. In both structures, only residues 19-30 of DARC are engaged by PvDBP, and this segment includes the Fy6 antigen [1, 3] . Isothermal titration calorimetry demonstrated a stepwise assembly mechanism in solution: the heterotrimer forms first with micromolar affinity followed by a second binding event to form the heterotetramer with nanomolar affinity. This stepwise binding mechanism results in a stable high-affinity complex to initiate invasion [31 && ]. Although these structural and biophysical studies provide deep mechanistic insight into DARC engagement by DBP, several unanswered questions remain. The glycine to aspartate change at residue 42 (FyB) increased DBP binding and P. vivax infection [55] and sulfation at residues 30 and 41 of DARC also increase binding to DBP [33] . However, residues 41 and 42 of DARC do not make direct contacts with DBP in the crystal structures [31 && ]. It is therefore plausible that these modifications to DARC may alter the surface exposure or presentation of the DARC N-terminus rather than facilitating a direct contact with DBP. Further studies are required to address these models.
BASIGIN
Basigin (BSG) is a 35-65 kDa glycoprotein composed of two to three extracellular immunoglobulin-like domains, a single span transmembrane domain, and a short cytoplasmic domain (Table 1) [1, 6] . BSG is expressed on number of cell types, including erythrocytes with 3000 copies per RBC [1, 3, 6] and has a broad range of functions. In RBCs, BSG is necessary for the correct surface targeting and activity of monocarboxylate trasporters [1, 6] .
An avidity-based screen optimized to detect lowaffinity interactions identified BSG as the receptor for P. falciparum reticulocyte-binding homology 5 (PfRh5), a member of the reticulocyte binding like homolog proteins (Rhs) (Fig. 1E , Table 2 ) [37] . PfRh5 binds to the short isoform of BSG that contains two immunoglobulin-like domains with a K d of 0. 43 ,40] that includes PfRipr, a large 123 kDa protein containing multiple EGF-like domains [40] , and PfCyRPA, a 35 kDa GPI-anchored protein [39 & ]. These weights suggest the 200 kDa complex is a 1 : 1 : 1 association of PfRH5, PfRIPR, and PfCyRPA. However, the molecular interactions within this complex are still unknown. BSG is an essential receptor for invasion by all strains of P. falciparum investigated [37] making this interaction central for malaria infection despite its relatively low abundance.
COMPLEMENT RECEPTOR 1
Complement receptor 1 (CR1) is a relatively low abundance, 50-1200 copies/cell, type 1 transmembrane protein on the surface of RBCs (Table  1) [7] . CR1 consists of up to 44 complement control protein (CCP) repeats organized into long homologous repeats composed of seven CCPs resulting in a protein of 190-280 kDa. CR1 binds C3b and C4b immune complexes resulting in transport of the complexes to the spleen and liver for clearance [7] .
CR1 is the receptor for PfRh4, a member of the Rh family [41, 42, 43 & ], as anti-CR1 antibodies block native PfRh4 binding to RBCs and soluble CR1 binds soluble PfRh4 with a K d of 2.9 mmol/l ( Fig. 1f , Table  2 ) [41] . PfRh4 binds to CCP1-3, which are also the repeats responsible for binding C4b and convertase decay-accelerating activity [42] . Surprisingly, C4b and PfRh4 are able to bind to CR1 at the same time. However, PfRh4 engagement of CR1 disrupts decay-accelerating activity in a dose dependent manner [42] .
More recently, the PfRh4 binding site was narrowed to CCP1 [43 & ]. Amino acid residues 18 and 20 are essential for binding and mutation of amino acids 7-9 and 19 greatly reduced binding to PfRH4. These residues form a continuous patch on one face of CCP1 [43 & ]. Although the regions of CR1 that interact with PfRh4 have been identified, the molecular architecture of the interaction remains unknown.
SEMAPHORIN 7A
Semaphorin 7A (Sema7A) is an 80 kDa GPI-anchored member of the semaphorin family [8, 9] composed of three domains: a sema domain, PSI domain, and immunoglobulin domain (Table 1) [8] . Sema7A is the receptor for the P. falciparum MTRAP (Fig. 1g , Table 2 ) [44] . PfMTRAP, a member of the thrombospondin-related anonymous protein (TRAP) family, is composed of receptor-binding extracellular domains, a transmembrane domain, and a cytoplasmic domain that facilitates active invasion utilizing an actin-myosin motor complex.
PfMTRAP's extracellular domain contains two thrombospondin repeat-like domains that are required to bind RBCs [45] . Direct binding studies showed the two thrombospondin repeat domains alone were necessary and sufficient to bind Sema7A with similar kinetics as the full length PfMTRAP ectodomain (K d ¼ 1.96 mmol/l and 1.18 mmol/l, respectively) [44] . The interaction is dependent on the sema domain, which promotes homodimerization of Sema7A [8] , and each PfMTRAP molecule binds a Sema7A monomer [44] . [51] . These proteins remain an area of active study to fully define the range of RBC interactions available to the malaria parasite.
NOVEL RECEPTORS AND LIGANDS WITH ROLES IN INVASION

CONSEQUENCES FOR THERAPEUTIC DESIGN
A mechanistic understanding of host-parasite receptor-ligand interactions and a mechanistic framework for antibody neutralization are crucial for the design of effective vaccines that will prevent malaria. Antibodies are a critical component of naturally acquired immunity to malaria. Although antibodies that target blood-stage parasites can prevent interactions, not all antibodies are inhibitory [36 && ,44,56] . It is clear that antibodies that target protein function by engaging to receptor-binding pockets or dimerization interfaces are potently neutralizing whereas antibodies that engage nonfunctional or decoy epitopes have no effect on parasite viability [56] . In addition, multiple interactions for RBC invasion indicate that targeting multiple parasite ligands will be necessary to prevent blood-stage infection. Lastly, polymorphic variation in parasite ligands results in immune evasion, and this phenomenon must also be addressed during vaccine design. This is best exemplified in PvDBP where recent efforts have proven successful in eliminating highly immunogenic polymorphic segments that result in strain-specific responses while retaining broadly neutralizing segments [57 & ,58 & ].
CONCLUSION
Recent advances have defined some of the interactions involved in malaria parasite invasion into RBCs. Receptors have been identified for four major families of Plasmodium invasion ligands (EBL, Rh, MSP, and TRAP) and the mechanisms of the interactions have been determined for a handful of the family members. Crystal structures of Plasmodium ligands alone and in complex with receptors have contributed greatly to the mechanisms of invasion. For those receptor/ligand pairs that have not been crystallized, mutagenesis studies have further elucidated how these pairs interact. In conclusion, red cell receptor engagement by malaria parasites is far more intricate than initially anticipated. Molecular mechanistic studies of host-parasite interactions remain an active area of research, and are desperately needed not only for the fundamental understanding of receptor biology but also for the rational design of vaccines and therapeutics for malaria.
